AZ Submits sNDAs for Seroquel XR

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca submitted two sNDAs to the FDA for once-daily Seroquel XR Extended-Release Tablets in the following indications: treatment of manic episodes associated with bipolar disorder and treatment of depressive episodes associated with bipolar disorder.     The bipolar mania submission is based on a study of once-daily treatment with Seroquel XR, compared to placebo, with a primary endpoint of change in YMRS (Young Mania Rating Scale) week three, in 316 patients suffering from bipolar mani...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters